InMode Ltd. (INMD)
| Previous close | 17.23 |
| Open | 17.01 |
| Bid | 17.15 x 400 |
| Ask | 17.25 x 100 |
| Day's range | 16.84 - 17.33 |
| 52-week range | 16.82 - 48.25 |
| Volume | |
| Avg. volume | 1,544,369 |
| Market cap | 1.455B |
| Beta (5Y monthly) | 2.16 |
| PE ratio (TTM) | 7.47 |
| EPS (TTM) | 2.30 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.60 |
ZacksEarnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Could The Market Be Wrong About InMode Ltd. (NASDAQ:INMD) Given Its Attractive Financial Prospects?
InMode (NASDAQ:INMD) has had a rough three months with its share price down 25%. However, stock prices are usually...
PR NewswireInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency b
